Overview
- Revolution Medicines reported that daraxonrasib patients lived a median 13.2 months versus 6.7 with standard second-line chemotherapy in a study of about 460 people.
- The once-daily oral drug is designed to block a protein mutated in more than 90% of pancreatic cancers, offering a targeted approach.
- Participants had advanced disease after prior chemotherapy, with half assigned to the pill and roughly 60 patients enrolled in France.
- Trial lead Dr. Brian Wolpin said the results mark a major advance that could change care for previously treated metastatic cases.
- French specialists said European access could come within months to two years, pending regulatory review and publication of full data.